No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
Immuneering Is Maintained at Buy by Chardan Capital
Immuneering Corp. Reports Promising Cancer Trial Results
Needham Maintains Immuneering(IMRX.US) With Buy Rating, Maintains Target Price $12
Immuneering Price Target Maintained With a $12.00/Share by Needham
Immuneering's Strategic Advancements and Financial Strength Bolster Buy Rating